Skin Surgery Techniques: Introduction

EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.

The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.

Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.